眾生藥業(002317.SZ):子公司一類創新藥RAY1216片Ⅲ期臨牀試驗完成首例受試者入組
格隆匯11月14日丨眾生藥業(002317.SZ)公佈,近日,公司控股子公司廣東眾生睿創生物科技有限公司(簡稱“眾生睿創”)組織開展的一類創新藥物RAY1216片,其用於治療輕型和普通型SARS-CoV-2感染患者的隨機、雙盲、安慰劑對照Ⅲ期臨牀研究完成首例受試者入組。
RAY1216靶向抑制3CL蛋白酶,抑制新冠病毒複製,作用機制明確,擁有全球自主知識產權。RAY1216片治療輕型和普通型SARS-CoV-2感染患者的隨機、雙盲、安慰劑對照Ⅲ期臨牀研究,擬入組1070例輕型和普通型新冠病毒感染患者,以安慰劑為對照,臨牀給藥方案為單藥RAY1216片,連續口服5天,主要終點指標為至臨牀症狀持續恢復的時間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.